Clinical trials in multiple myeloma evaluating non–BCMA-directed CAR T-cell constructs
| Trial . | Sponsor . | CAR name . | ScFv origin . | Phase . | n . | Antigen . | Costimulatory domain . | Cell source . | Transfer method . | Dose . | Efficacy . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04499339 | European Union & CARAMBA | CARAMBA | Murine | 1 | 38 | SLAMF7 | NR | Autologous | Sleeping beauty | NA | NR |
| NCT02135406 | University of Pennsylvania | CTL019 | Murine | 1 | 10 | CD19 | 4-1BB | Autologous | Lentiviral | 1.1-6 × 108 | VGPR: 6; PR: 2; PD: 2 |
| NCT01886976 | Chinese PLA General Hospital | CART-138 | Murine | 1/2 | 5 | CD138 | 4-1BB | Autologous | Retroviral | 0.44-1.51 × 107 | SD: 4; PD: 1 |
| NCT00881920 | Baylor College of Medicine | κ.CARTs | Murine | 1 | 7 | κ light chain | CD28 | Autologous | Retroviral | 2.0 × 108 | 4 SD |
| NCT03958656 | National Cancer Institute | NA | NA | 1 | 42 | SLAMF7 | CD28 or 4-1BB/ CD3z + inducible caspase 9 (IC9) cell suicide | Autologous | NA | 0.3-12.0 × 106 | NA |
| NCT04142619 | Cellectis S.A. | UCARTCS1 | NA | 1 | 18 | SLAMF7 (TALEN-targeted gene editing TCR and SLAMF7) | 4-1BB | Allogeneic | NA | NA | NA |
| NCT02203825 | Celyad | NKG2D-CAR | Human | 1 | 12 | NKG2D ligands | DAP10 | Autologous | Retroviral | 1-3 × 107 | NA |
| NCT03464916 | Sorrento Therapeutics | CAR2 anti- CD38 A2 | NA | 1 | 72 | CD38 | NA | Autologous | NA | NA | NA |
| EU-CART | EU Horizon 2020 Program | NA | NA | 1 | NA | CD44v6 (+HSV-TK suicide gene) | CD28 | Autologous | Retroviral | NA | NA |
| NCT01716364 | Peter MacCallum Cancer Centre, Australia | LeY | NA | 1 | 6 | Lewis Y | CD28 | Autologous | Retroviral | NA | NA |
| NCT05016778 | Zhejiang University | GPR5D-CAR T | NA | 1 | 15 | GPRC5d | NA | Autologous | NA | 1.0, 3.0, or 6.0 × 106/kg | NA |
| NCT05219721 | Tongji Hospital | CAR-GPR5D | Human | 1 | 18 | GPRC5d | 4-1BB | Autologous | NA | 0.5, 1.0, and 2.0 × 106/kg | NA |
| NCT04555551 | Memorial Sloan Kettering Cancer Center | MCARH109 | Human | 1 | 17 | GPRC5d | 4-1BB | Autologous | Lentiviral | 25, 50, 150, 450 × 106 | ORR 69% CR 25% |
| Trial . | Sponsor . | CAR name . | ScFv origin . | Phase . | n . | Antigen . | Costimulatory domain . | Cell source . | Transfer method . | Dose . | Efficacy . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04499339 | European Union & CARAMBA | CARAMBA | Murine | 1 | 38 | SLAMF7 | NR | Autologous | Sleeping beauty | NA | NR |
| NCT02135406 | University of Pennsylvania | CTL019 | Murine | 1 | 10 | CD19 | 4-1BB | Autologous | Lentiviral | 1.1-6 × 108 | VGPR: 6; PR: 2; PD: 2 |
| NCT01886976 | Chinese PLA General Hospital | CART-138 | Murine | 1/2 | 5 | CD138 | 4-1BB | Autologous | Retroviral | 0.44-1.51 × 107 | SD: 4; PD: 1 |
| NCT00881920 | Baylor College of Medicine | κ.CARTs | Murine | 1 | 7 | κ light chain | CD28 | Autologous | Retroviral | 2.0 × 108 | 4 SD |
| NCT03958656 | National Cancer Institute | NA | NA | 1 | 42 | SLAMF7 | CD28 or 4-1BB/ CD3z + inducible caspase 9 (IC9) cell suicide | Autologous | NA | 0.3-12.0 × 106 | NA |
| NCT04142619 | Cellectis S.A. | UCARTCS1 | NA | 1 | 18 | SLAMF7 (TALEN-targeted gene editing TCR and SLAMF7) | 4-1BB | Allogeneic | NA | NA | NA |
| NCT02203825 | Celyad | NKG2D-CAR | Human | 1 | 12 | NKG2D ligands | DAP10 | Autologous | Retroviral | 1-3 × 107 | NA |
| NCT03464916 | Sorrento Therapeutics | CAR2 anti- CD38 A2 | NA | 1 | 72 | CD38 | NA | Autologous | NA | NA | NA |
| EU-CART | EU Horizon 2020 Program | NA | NA | 1 | NA | CD44v6 (+HSV-TK suicide gene) | CD28 | Autologous | Retroviral | NA | NA |
| NCT01716364 | Peter MacCallum Cancer Centre, Australia | LeY | NA | 1 | 6 | Lewis Y | CD28 | Autologous | Retroviral | NA | NA |
| NCT05016778 | Zhejiang University | GPR5D-CAR T | NA | 1 | 15 | GPRC5d | NA | Autologous | NA | 1.0, 3.0, or 6.0 × 106/kg | NA |
| NCT05219721 | Tongji Hospital | CAR-GPR5D | Human | 1 | 18 | GPRC5d | 4-1BB | Autologous | NA | 0.5, 1.0, and 2.0 × 106/kg | NA |
| NCT04555551 | Memorial Sloan Kettering Cancer Center | MCARH109 | Human | 1 | 17 | GPRC5d | 4-1BB | Autologous | Lentiviral | 25, 50, 150, 450 × 106 | ORR 69% CR 25% |
NA, not available; NR, not reached; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial response.